REG - BSF Enterprise PLC - 3D Bio-Tissues enters partnership with New Harvest

BSF EnterpriseAnnouncement

19/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221219:nRSS1329Ka&default-theme=true

RNS Number : 1329K  BSF Enterprise PLC  19 December 2022

 

19 December 2022

BSF Enterprise PLC

("BSF" or the "Company")

3D Bio-Tissues enters partnership with New Harvest

BSF (LSE:BSFA), an investment company focused on unlocking the next generation
of biotech solutions and the development of lab-grown tissues, is pleased to
announce that its 100% owned subsidiary, 3D Bio-Tissues Ltd ("3DBT"), has
commenced a formal consulting collaboration with Stichting New Harvest
Netherlands ("New Harvest"), a non-profit organisation dedicated to advancing
cellular agriculture, focused on advancing 3DBT's route-to-market strategy and
accelerating the commercialisation of its products worldwide.

 

New Harvest will provide 3DBT with a clear and comprehensive roadmap of the
safety and regulatory requirements of animal-free media, its ingredients and
derivatives in the European Union, UK, and others as time allows. The project
is focused on aligning 3DBT's innovative City-mix™ cell-boosting supplements
with existing international standards, including regulatory pathways for
chemicals or substances added to food which have previously been deemed safe
by experts.

The project, which will be undertaken over the next 12 months, will include:

 

●      Expert analysis on the current regulatory and safety legislation
relating to the manufacture and utilisation of animal-free media

●      Predicted milestones and corresponding timeframes

●      Defined action points

 

New Harvest is currently advancing understanding in the safety of cultivated
meat and seafood research in partnership with various governments and
intergovernmental organisations such as the Food and Agriculture Organization
("FAO") of the United Nations to drive forward a clear global framework for
cultivated meat production with the overall aim of providing products to a
growing market as well as significantly reducing greenhouse gas emissions from
food production.

Che Connon, Chief Executive of 3D-Bio Tissues, said: "Today's announcement
marks the start of a significant workstream focused on putting affordable
cultivated meat on shelves. New Harvest's partnerships across government and
industry are integral to helping accelerate breakthroughs in cellular
agriculture and laying the foundations for companies like 3DBT to drive the
adoption of our products on a mass-scale. We look forward to working with them
as we continue to unveil further larger-scale prototypes and the UK's first
lab-grown fillet in the coming months."

Isha Datar, Executive Director of New Harvest, said: "Bringing together the
public and private sectors to advance cellular agriculture is critical to our
collective mission and success. We are delighted to be working with the team
at 3DBT on bringing more real-world understanding and information on the
safety and regulatory aspects of cell cultured meat and seafood to the public.
Their product and their collaborative approach will be of benefit to the
entire field at large."

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                      Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                             0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                             020 3757 6882

 Elisabeth Cowell                        BSF@secnewgate.co.uk

 George Esmond

 

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultivated meat, lab-grown leather, as well as human corneas,
collagen growth and skin substitutes, as part of a radical transformation to
deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues Ltd (3DBT), a tissue engineering company with
patent-protected IP that is already producing human corneas that will help
restore vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRGPGUGPUPPUQB